-27%

Microgynon Fe Tablets, 28 Tablets

We appreciate your interest in our products. Please be advised that the prices advertised on our website are subject to change without prior notice. Due to various factors such as supplier costs, market fluctuations, and other variables, the prices may vary over time.To ensure that you have the most accurate and up-to-date information regarding product prices, we kindly encourage you to contact our pharmacy directly 09034553795 or order via WhatsApp

Effective contraception pills

1,200.00 or subscribe and save 10%

Availability: In Stock

Save 10% when you schedule repeat purchases
• No Fees
• Cancel anytime

- +
Compare

Compare
EAN: 5016723003939 SKU: PILLS013 Category:

Frequently Bought Together

Microgynon Fe Tablets, 28 Tablets
1,200.00 or subscribe and save 10%
 + 
Vitabiotics Wellwoman Plus Tablets, 56 Tablets
13,750.00 or subscribe and save 10%

Microgynon Fe Tablets, 28 Tablets

Discover Freedom with Microgynon Fe Tablets – Your Trusted Companion in Contraception

Microgynon Fe Tablets bring you the assurance of a reliable and effective combined contraceptive pill, providing a comprehensive solution for preventing unwanted pregnancies when taken as directed. Empowering women with control over their reproductive choices, Microgynon Fe is designed to offer peace of mind and convenience.

Key Features:

  1. Proven Effectiveness: Microgynon Fe is a tried and tested combined contraceptive pill that has demonstrated remarkable efficacy in preventing pregnancy when taken correctly. With a well-established track record, it provides the reliability women need in their family planning journey.
  2. Convenience of a Combined Pill: Microgynon Fe combines two essential hormones, estrogen, and progestogen, working in tandem to inhibit ovulation, thicken cervical mucus, and alter the uterine lining – collectively ensuring a robust defense against conception. The convenience of a single pill makes it an easy and user-friendly choice.
  3. Regularity and Predictability: With Microgynon Fe, you can embrace a routine that aligns with your lifestyle. The tablet’s consistent and predictable daily use ensures optimal contraceptive protection, helping you plan and manage your contraception effortlessly.
  4. Additional Benefits of Iron Supplementation: Beyond its contraceptive efficacy, Microgynon Fe goes the extra mile by incorporating iron supplementation. This thoughtful addition helps combat iron deficiency anemia, addressing a common concern among women and contributing to overall well-being.
  5. Trusted by Healthcare Professionals: Microgynon Fe is a product backed by the confidence of healthcare professionals worldwide. Its formulation and effectiveness are well-recognized, making it a trusted choice for women seeking a reliable and convenient contraceptive solution.
  6. Easy to Start, Simple to Maintain: Microgynon Fe is designed to be user-friendly. Whether you’re starting a new contraceptive regimen or transitioning from another method, these tablets offer a seamless and straightforward integration into your daily routine.

Take charge of your reproductive health with Microgynon Fe Tablets – the combined contraceptive pill that prioritizes reliability, effectiveness, and your peace of mind. Consult with your healthcare provider to determine if Microgynon Fe is the right choice for you, and embark on a journey towards confident and responsible family planning.

Can someone who is pregnant or breastfeeding use Microgynon Fe Tablets?

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking Microgynon Fe Tablets.

Microgynon Fe Tablets Reviews

After using Microgynon Fe Tablets, it’s helpful to let others know about your experience. Reviews of an item help other users know that medicines received have helped the condition it is claimed for, how well the treatment worked or any issues to be aware of. We invite our users to leave a review of both their treatment and of the service provided. Click on the reviews tab to see if there has been feedback on this item.

What is the price of  Microgynon Fe Tablets in Nigeria?

The price of  Microgynon Fe Tablets is N1200

Where can you buy Microgynon Fe Tablets In Nigeria?

You can Buy Microgynon Fe Tablets at Asset Pharmacy Lagos Nigeria, Nigeria’s Largest Online Pharmacy.

Microgynon Fe Tablets is not available to buy over the counter. You need a prescription to buy Microgynon Fe Tablets

Microgynon Fe Tablets is a prescription drug that legally requires a medical prescription to be dispensed.
To order this product you confirm that you are under the care of your doctor or consultant and have been given permission by them for purchase, fulfillment & use in treatment with their written consent via prescription.

You will be required to send Asset Pharmacy your prescription

Brand

Microgynon

How to Use

How to use

The tablets must be taken at approximately the same time each day, if required with some liquid, in the sequence stated on the blister. The tablets are taken continuously

1 tablet must be taken daily for 28 consecutive days

Tablet-taking from the next pack is started after the last tablet from the previous pack has been taken.

Withdrawal bleeding generally starts 2 to 3 days after starting to take the placebo tablets. It may persist when tablet-taking from the next pack has been commenced.

Starting to take Microgynon 28

No preceding use of hormonal contraceptives [within the last month] Tablet-taking should commence on day 1 of the natural cycle (i.e. on the first day of menstrual bleeding). If commenced between days 2 and 5, an additional contraceptive method is recommended for the first 7 days of the first treatment cycle.

Switching from another combined hormonal contraceptive (COC, vaginal ring, transdermal patch) The user should preferably start taking Microgynon Fe on the day after taking the last active tablet of her previous combined product (or after removal of the ring or patch), but by no later than the day after the usual tablet-free (ring-free, patch-free) interval, or on the day after taking the last inactive tablet of the previous combined product.

Switching from a progestogen-only product (pill, injection, implant) or an intrauterine system (IUS)

In women previously taking the minipill, the switch can be made on any day of their choice (the switch from an implant or intrauterine system must take place on the day of its removal; the switch from an injectable must take place at the time when the next injection would be due). However, in all cases, an additional contraceptive method is required during the first 7 days of tablet-taking.

Following a first-trimester abortion Tablet-taking can commence immediately.

In this case, no additional contraceptive measures are required.

Following childbirth or a second-trimester abortion

For use during breast-feeding,  Tablet-taking should commence on days 21 to 28 following childbirth or after a second-trimester abortion. If started any later, a barrier method must additionally be used during the first 7 days of tablet-taking. However, if sexual intercourse has already taken place, pregnancy must be excluded before the tablets are started, or the woman must wait for her first menstrual period

Product Details

Product Information

Contraindications

Combined oral contraceptives (COCs) must not be used in the presence of any of the following conditions. If any of these conditions occurs for the first time during COC use, the medicinal product must be discontinued immediately. – Presence or risk of venous thromboembolism (VTE) – venous thromboembolism – existing VTE (including during therapy with anticoagulants) or history of VTE (e.g. deep vein thrombosis [DVT] or pulmonary embolism [PE]) – known hereditary or acquired predisposition for venous thromboembolism, e.g. APC resistance (including Factor V Leiden), antithrombin III deficiency, protein C deficiency or protein S deficiency – major surgery with prolonged immobilisation (see section 4.4) – high risk of venous thromboembolism due to several risk factors (see section 4.4) – Presence or risk of arterial thromboembolism (VTE) – arterial thromboembolism – existing ATE, history of ATE (e.g. myocardial infarction) or disease at the prodromal stage (e.g. angina pectoris) – cerebrovascular disease – existing stroke, history of stroke or prodromal disease (e.g. history of transient ischaemic attack [TIA]) – known hereditary or acquired predisposition for arterial thromboembolism, e.g. hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant) – history of migraine with focal neurological symptoms – high risk of arterial thromboembolism due to several risk factors (see section 4.4) or a serious risk factor, such as: – diabetes mellitus with vascular damage – severe hypertension – severe dyslipoproteinaemia – Existing or previous pancreatitis, if accompanied by severe hypertriglyceridaemia – Existing or previous severe hepatic disease, until liver function values have returned to normal – Existing or previous liver tumours (benign or malignant) – Known or suspected sex hormone-dependent malignant tumours (e.g. of the genital organs or breast) – Undiagnosed vaginal bleeding – Amenorrhoea of unknown cause – Hypersensitivity to the active substances levonorgestrel and ethinylestradiol or to any of the excipients listed in section 6.1. The simultaneous use of Microgynon Fe together with medicines containing ombitasvir/paritaprevir/ritonavir and dasabuvir is contraindicated

Special warnings and precautions for use

Warnings

The suitability of Microgynon Fe should be discussed with the woman if any of the following disorders or risk factors is present. If any of these disorders or risk factors deteriorates or appears for the first time, the user should be advised to contact her doctor to decide whether the use of Microgynon Fe should be terminated. 5 Risk of venous thromboembolism (VTE) The use of any combined hormonal contraceptive (CHC) increases the risk of venous thromboembolism (VTE) compared with non-use. The decision to use Microgynon Fe should be taken only after discussion with the woman, during which it should be ensured that she understands the following: – the risk of VTE with Microgynon Fe use, – how her existing, individual risk factors influence this risk, – and that her risk of VTE is highest during her very first year of use. There are also indications that the risk is increased when CHC use is resumed after an interval of 4 weeks or more. Approximately 2 out of 10,000 women not using a CHC and who are not pregnant will suffer a VTE during the course of a year. However, the risk may be significantly higher in individual women, depending on their underlying risk factors (see below). Approximately 61 out of 10,000 women using a levonorgestrel-containing CHC will suffer a VTE during the course of a year. The number of VTEs per year with low-dose CHCs is lower than the expected number during pregnancy or in the postpartum period. VTEs are fatal in 1-2% of cases.

Fertility, pregnancy and lactation

Pregnancy

Microgynon Fe is not indicated during pregnancy. If pregnancy occurs during use of Microgynon 28, the product must be withdrawn immediately. In most of the epidemiological studies, no increased risk of malformations was found in children whose mothers had taken combined oral contraceptives before pregnancy, or any teratogenic effect when combined oral contraceptives were inadvertently taken during early pregnancy.

Breastfeeding

COCs can affect lactation, as they can reduce the quantity of breast milk and alter its composition. COC use is therefore not recommended until the mother has completely weaned her infant. Small amounts of contraceptive steroids and/or their metabolites may be excreted in breast milk. These amounts might adversely affect the infant. The increased VTE risk in the postpartum period should be considered prior to reuse after a break in administration

Side Effects

Undesirable effects

The most common adverse reactions associated with the use of EE/LNG-containing combined oral contraceptives are headache, spotting and intermenstrual bleeding.

Other adverse reactions reported in users of EE/LNG-containing oral combined hormonal contraceptives, to which Microgynon Fe also belongs, are:

venous thromboembolic disorders; – arterial thromboembolic disorders; – cervical cancer; 13 – hypertension; – hypertriglyceridaemia; – effects on peripheral insulin resistance and glucose tolerance; – hepatic tumours; – hepatic dysfunction; – chloasma; Crohn’s disease, ulcerative colitis; – epilepsy; – migraine; – endometriosis, uterine fibroids; – porphyria; – systemic lupus erythematosus; – herpes gestationis; – Sydenham’s chorea; – haemolytic-uraemic syndrome; – cholestatic jaundice – otosclerosis. The frequency of breast cancer diagnosis is slightly increased among OC users. As breast cancer rarely occurs in women under 40 years, the risk of contracting breast cancer is low compared with the overall risk. There is no known causal relationship with COC use

 

Ingredients

Product Ingredients

Each blister contains 21 beige-coloured, active tablets and 7 brown inactive tablets.

Active Ingredients:

One coated tablet contains 150 µg levonorgestrel and 30 µg ethinylestradiol.

Inactive tablets:

Ferrous fumarate, lactose monohydrate, maize starch, povidone K25, talc, magnesium stearate

How to store

How to store

Do not store above 30 °C.

Patient Information Leaflet

Click here  for the Patient Information Leaflet

Delivery

Delievry time are estimates. Can vary due to the time of day you order.

Delivery time estimate are subject to the courier company.

Shipping to Lagos cost starts from N1850 Next day delivery

Shipping to Rest Of Nigeria – 2-3 days cost starts from N2000

Shipping to Rest of Africa –  5-7 working days Cost starts from N12000

Shipping to Europe 7 – 14 working days Cost srats from N18000

Shipping to Rest of the world – 7 – 14 days Cost starts from N18000

Back to top
error:
Hi there, How can I help
X